Objectives The goal of this study was to investigate sex-based differences in long-term clinical and angiographic outcomes after coronary revascularization with drug-eluting stents (DES).
More than 1 million percutaneous coronary interventions (PCI) are performed each year in the United States with one-third of procedures performed in women (1) . Female patients differ from their male counterparts in terms of age (2) , cardiovascular risk factors (3) , clinical presentation (4, 5) , and angiographic characteristics, including vessel size and extent of disease (4, 6) . Early studies during the balloon angioplasty era reported a lower procedural success, a higher in-hospital mortality, and impaired long-term clinical outcomes among women compared with men (2, 3, 7, 8) .
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Bare-metal stents improved outcomes after PCI among women (4,9 -12) in terms of safety and efficacy. The advent of drug-eluting stents (DES) has led to important reductions in restenosis and repeat revascularization rates compared with bare-metal stents (13) , and DES are used in more than 80% of patients undergoing PCI in the United States (1) . However, sex-related differences in clinical and angiographic outcomes after revascularization with DES are not well established (14 -17 (18) (19) (20) and compared clinical and angiographic outcomes between women and men during long-term follow-up through 2 years.
Methods
Study population. Individual data were pooled for 5,011 patients from 3 large randomized clinical trials investigating the unrestricted use of DES for coronary revascularization: the SIRTAX trial (18) , the LEADERS trial (19) , and the RESOLUTE All-Comers trial (20) . All trials were conducted between 2004 and 2009 at European institutions, with the exclusive use of DES and an all-comers study design. Inclusion criteria were broad to reflect routine clinical practice. Patients with either stable coronary artery disease or acute coronary syndrome (including patients with unstable angina, non-ST-segment elevation and STsegment elevation myocardial infarction) were eligible, if they had at least 1 lesion with diameter stenosis of 50% or more in a vessel with reference diameter of 2.25 to 4.0 mm (SIRTAX and RESOLUTE All-Comers) and 2.25 to 3.5 mm (LEAD-ERS) (18) (19) (20) . None of the trials had any restriction with respect to number of treated lesions, treated vessels, lesion length, or number of stents implanted. Exclusion criteria were few and included known intolerance to the study drugs, metal alloys, or contrast media, planned surgery within 6 months after the index procedure, and participation in another study. Angiographic follow-up was planned at 8 months among patients included in SIRTAX, at 9 months among 25% of patients included in LEADERS, and at 13 months among 20% of patients in RESOLUTE All-Comers. The trials complied with the provisions of the Declaration of Helsinki, and the study protocols were approved by the institutional review board at each study center. All patients provided written informed consent for participation in the study. Procedures. Randomization was done after diagnostic angiography and before PCI in all 3 trials. In the SIRTAX trial (18) , patients were randomly allocated to receive sirolimus-eluting stents (Cypher, Cordis, Johnson & Johnson, Miami Lakes, Florida) or paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, Massachusetts); in the LEADERS trial (19) , patients were randomly allocated to receive biolimuseluting stents (BioMatrix, Biosensors, Newport Beach, California) or sirolimus-eluting stents (Cypher, Cordis); and in the RESOLUTE All-Comers trial (20) , patients were randomly allocated to receive zotarolimus-eluting stents (Resolute Endeavor, Medtronic, Santa Rosa, California) or everolimuseluting stents (Xience V, Abbott Vascular, Santa Clara, California). Balloon angioplasty and stent implantation were performed according to standard techniques and in accordance with guidelines; direct stenting was allowed. Full lesion coverage was attempted by implanting 1 or several stents. No mixture of type of stents was permitted for a given patient unless the operator was unable to insert the study stent, in which case crossover to another device of the operator's choice was possible. In case of unplanned revascularization procedures requiring stent implantation, it was recommended that physicians use the same type as the initially allocated study stent. Procedural anticoagulation was achieved with unfractionated heparin at a dose of 5,000 IU or 70 to 100 IU/kg of body weight; the use of glycoprotein IIb/IIIa inhibitors was left to the operator's discretion. Dual antiplatelet therapy consisting of acetylsalicylic acid of at least 75 mg once daily and the thienopyridine clopidogrel 75 mg daily was prescribed for at least 12 months in the SIRTAX and LEADERS trials, and for at least 6 months in the RESOLUTE All-Comers trial. Definitions. The primary endpoint of the present study was the composite of cardiac death and myocardial infarction (MI) at 2 years. Secondary clinical endpoints were the individual components of the primary endpoint as well as all-cause death, the composite of all-cause death and MI, clinically indicated target lesion and target vessel revascularization, and definite and definite or probable stent thrombosis according to the Academic Research Consortium criteria (21) . For each trial, a blinded clinical events committee independently adjudicated all adverse events. Endpoint definitions were comparable across the 3 trials. Cardiac death was defined as death from cardiac causes or any death from unknown causes in SIRTAX and LEADERS, and as any death unless an undisputed noncardiac cause was present in RESOLUTE All-Comers. MI was defined-in SIRTAX and LEADERS trials-as the presence of new Q waves in at least 2 contiguous leads and an elevated creatine kinase-MB fraction, or-in the absence of significant Q waves-as an increase in the creatine kinase level to more than twice the upper limit of the normal range with an elevated level of creatine kinase-MB or troponin (18, 19) . In the RESOLUTE All-Comers trial, MI was defined according to an "extended historical" definition (20, 22) , consistent with the 1 used in SIRTAX and LEADERS. Target lesion revascularization was defined as any revascularization for a stenosis within the stent or within a 5-mm border proximal and distal to the stent in all 3 trials. A revascularization was considered clinically indicated in the presence of angiographic diameter stenosis of at least 50% and ischemic signs or symptoms, or with angiographic diameter stenosis of at least 70% regardless of ischemic signs or symptoms (18 -20) .
Secondary angiographic endpoints were late lumen loss (i.e., difference between the post-procedure and follow-up minimal lumen diameter), rate of binary restenosis (i.e., % diameter stenosis of at least 50%), percent diameter stenosis (i.e., reference vessel diameter Ϫ minimal lumen diameter/ reference vessel diameter ϫ 100), and minimal lumen diameter. Angiographic endpoints were considered for both the in-stent (i.e., within the stent) and in-segment (i.e., within the stent and a 5-mm border proximal and distal) analysis. For a detailed description of quantitative coronary angiography methods, we refer to the principal publications of the 3 trials (18 -20) . SYNTAX score was assessed by a central core laboratory (Cardialysis, Rotterdam, the Netherlands) in all 3 trials. Statistical analysis. Of 5,011 patients randomized in the 3 trials, 4,885 (97.5%) patients completed 2 years of follow-up according to the pre-specified definition (i.e., last medical contact 720 days after the index procedure, with a 30-day window) and were included in the present analysis. Comparison between women and men were carried out using mixed models with random effects specified as type of randomized clinical trial as random intercept, and treatment arms as random coefficients. Mixed maximum logistic regression models were used to derive differences between female and male patients for binary and continuous outcomes, respectively. The percentages were predicted probabilities derived from mixed maximum logistic regression models. Means and standard deviations were predicted values derived from mixed maximum likelihood regression models. Odds ratios (ORs) and confidence intervals (CIs) were adjusted for stent type in the crude analysis, whereas the adjusted Values are mean Ϯ SD or n (%).
CABG ϭ coronary artery bypass graft; CI ϭ confidence interval; MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention.
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Stefanini et al. Table 2 . Women had a smaller reference diameter of the Values are mean Ϯ SD or n (%).
CI ϭ confidence interval; MLD ϭ minimal lumen diameter; RVD ϭ reference vessel diameter. Values are n (%).
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OR ϭ odds ratio; TLR ϭ target-lesion revascularization; TVR ϭ target-vessel revascularization; other abbreviations as in Table 1 . Values are n (%).
Abbreviations as in Tables 1 and 3 .
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Unrestricted Use of DES in Women and Men
Cumulative events curves for definite and definite or probable stent thrombosis stratified according to sex are shown in Figure 2 . There was no difference in the risk of stent thrombosis between women and men in terms of definite (1.7% vs. 1.7%, adjusted OR: 0.68, 95% CI: 0.33 to 1.39, p ϭ 0.29) and definite or probable stent thrombosis (2.2% vs. 2.2%, adjusted OR: 0.73, 95% CI: 0.38 to 1.38, p ϭ 0.33) at any time point (Table 5) . Angiographic outcomes. Protocol-mandated angiographic follow-up was available for 1,561 lesions: 351 lesions among 260 women and 1,210 lesions among 876 men. With respect to baseline clinical characteristics, patients with, as compared to those without, angiographic follow-up were younger (62.6 Ϯ 10.7 vs. 64.3 Ϯ 10.8, p Ͻ 0.001), more frequently smokers (32.7% vs. 26.1%, p ϭ 0.05), and less frequently treated with previous coronary artery bypass graft (4.1% vs. 10.6%, p Ͻ 0.001). Crude and adjusted results of angiographic outcomes according to sex are presented in Table 6 . There were no differences in terms of in-stent late lumen loss (0.18 Ϯ 0.54 mm vs. 0.20 Ϯ 0.99 mm, p ϭ 0.76) and in-segment binary restenosis (8.5% vs. 8.5%, p ϭ 0.76) (Fig. 3 ) between women and men during follow-up angiography. Paired angiographic findings for in-stent minimal lumen diameter at baseline, immediately after the intervention and at the time of angiographic follow-up showed no differences between women and men (Fig. 4) .
Discussion
The present analysis represents the largest investigation of sex-based clinical and angiographic outcomes in a population pooled from 3 large randomized clinical trials with the unrestricted use of DES and follow-up through 2 years. Our findings can be summarized as follows:
1. Women undergoing PCI with the unrestricted use of DES differ from their male counterparts and are typically older, have more cardiovascular risk factors except for smoking, and a lower degree of angiographic complexity as assessed by the SYNTAX score. 2. After controlling for baseline differences, women undergoing PCI with DES have a similar risk of cardiac death and MI as compared with men through 2 years of follow-up. 3. DES achieve equivalent safety and efficacy in women and men with similar results in terms of stent thrombosis, repeat revascularization, and angiographic outcomes through 2 years of follow-up.
Early studies evaluating sex-based differences in outcomes after PCI in the balloon angioplasty era reported disparate results, but in general showed worse in-hospital and long-term clinical outcomes among women compared with men, with higher rates of in-hospital mortality and more frequent recurrent angina during long-term follow-up (2, 3, 7, 8, 23) . This "gender gap" did largely decrease with the advent of bare-metal stents. Indeed, advances in technology leading to smaller guiding and balloon catheters resulted in more favorable outcomes in women with similar angiographic and procedural success rates despite smaller vessel size (10) . Moreover, the use of bare-metal stents improved long-term outcomes among women (4,9 -12), particularly as related to the risk of repeat revascularization. However, women still showed a higher risk of mortality during the short term (30 days) that persisted after adjustment for baseline clinical dif- Adjusted odds ratios (OR) and 95% confidence intervals (CI) for cardiac death or myocardial infarction (MI), cardiac death, MI, clinically indicated target lesion revascularization (TLR), and target vessel revascularization (TVR) at 2 years. Unrestricted Use of DES in Women and Men observations came from the TAXUS Woman analysis (17) , comparing outcomes between 665 women and 1,606 men treated with paclitaxel-eluting or bare-metal stents included into 5 randomized clinical trials in an "on-label" setting, as well as 1,528 women and 3,266 men with an "expanded" indication within 2 large "real-world" registries. The present study extends the available evidence to a large and homogenous cohort of women and men who were treated with the unrestricted use of DES in an all-comers patient population, including STelevation MI, and a high prevalence of "off-label" indications. The similar outcomes in terms of cardiac death, MI, and stent thrombosis are reassuring and reinforce the lack of a sex gap in terms of patient and device safety. Along the same line, the present study provides robust evidence that DES achieve comparable efficacy in women and men. Rates of clinical revascularization showed no difference despite a somewhat lower baseline reference vessel diameter among women. Moreover, detailed angiographic analysis showed similar acute and long-term performance of DES irrespective of sex as evidenced by comparable post-procedural and follow-up minimal lumen diameter dimensions (Fig. 4) . Finally, the results confirm similar potency of DES in the suppression of neointimal hyperplasia as evidenced by the in-stent late loss and in-segment restenosis. Mehilli et al. have previously described a lower risk of clinical and angiographic restenosis in women as compared with men undergoing PCI using bare-metal stents (6) . Conversely, we observed a similar risk of angiographic and clinical restenosis Values are n (%). Tables 2 and 3 . Values are mean Ϯ SD or n (%).
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Abbreviations as in
Abbreviations as in Tables 2 and 3 . among women and men irrespective of the type of DES used, indicating that DES efficacy is largely independent of patient sex. Recently, 2 large investigations underscored sex differences in delivery of evidence-based therapies and clinical outcomes among patients with coronary artery disease (25, 26) . In the present study, women presented with more advanced age and a greater prevalence of diabetes and hypertension, resulting in an overall higher clinical risk profile at baseline. The latter contributed to higher crude event rates among women, which were no longer apparent following adjustment for differences in baseline characteristics. The present study does not address why women present later and have a higher clinical risk profile at the time of revascularization. However, it is notable that the angiographic risk as assessed by the SYNTAX score was lower among female than male patients, suggesting that the extent of coronary artery disease was less severe despite the more unfavorable clinical characteristics. Study limitations. First, this is an analysis of individual patient data pooled from 3 randomized clinical trials not primarily intended to investigate sex-based differences in outcomes. However, the large number of included patients provides sufficient precision to evaluate differences between women and men in a large spectrum of patients. Second, 5 different types of DES were used for implantation in 3 different studies. However, we analyzed differences by the use of mixed models accounting for the different studies included in the present analysis as well as treatment arms. Moreover, the use of different types of DES provides a certain degree of generalizability of our findings to DES as a class treatment effect. Finally, the angiographic follow-up was not available for all included patients. Nevertheless, the consistency of angiographic results and the correlation with clinical efficacy support our findings of equivalent efficacy of DES in women and men undergoing PCI.
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Conclusions
The unrestricted use of DES is associated with similar long-term safety and efficacy among women and men with coronary artery disease requiring revascularization.
